Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG

Blood
Jan BraessWolfgang Hiddemann

Abstract

Dose density during early induction has been demonstrated to be one of the prime determinants for treatment efficacy in acute myeloid leukemia (AML). The German AML Cooperative Group has therefore piloted a dose-dense induction regimen sequential high-dose AraC and mitoxantrone followed by pegfilgrastim (S-HAM) in which 2 induction cycles are applied over 11 to 12 days instead of 25 to 29 days as used in conventional double induction, thereby increasing dose density 2-fold. Of 172 de novo AML patients (excluding acute promyelocytic leukemia), 61% reached a complete remission, 22% a complete remission with incomplete peripheral recovery, 7% had persistent leukemia, 10% died (early death) resulting in an overall response rate of 83%. Kaplan-Meier estimated survival at 2 years was 61% for the whole group (patients with unfavorable karyotypes, 38%; patients with favorable karyotypes, 69%; patients with intermediate karyotypes, 75%) after S-HAM treatment. Importantly, the compression of the 2 induction cycles into the first 11 to 12 days of treatment was beneficial for normal hematopoiesis as demonstrated by a significantly shortened duration of critical neutropenia of 31 days compared with 46 days after conventionally timed double ...Continue Reading

References

Sep 30, 1999·The New England Journal of Medicine·B LöwenbergA Burnett
Jul 28, 2001·Seminars in Hematology·W Hiddemann, T Büchner
Mar 21, 2002·Nature Reviews. Cancer·J D Rowley
Feb 4, 2003·Nature Reviews. Cancer·Daniel G Tenen
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Sep 21, 2004·Oncogene·Jennifer K WarnerJohn E Dick
Oct 21, 2005·Critical Reviews in Oncology/hematology·Björn SteffenHubert Serve

❮ Previous
Next ❯

Citations

Jul 5, 2011·Current Oncology Reports·Jenna Vanliere CanzonieroIvana Gojo
Aug 12, 2009·Current Opinion in Oncology·Francesco BuccisanoAdriano Venditti
Aug 5, 2009·Current Opinion in Hematology·Hans-Jochem KolbChristoph Schmid
Jan 21, 2010·Current Opinion in Hematology·Hugo F Fernandez, Jacob M Rowe
Mar 15, 2011·Blood·William A Wood, Stephanie J Lee
Apr 16, 2014·PloS One·Friederike PastoreKarsten Spiekermann
Mar 14, 2012·Der Internist·M Fiegl, W Hiddemann
Sep 13, 2014·Journal of Hematology & Oncology·Friederike PastoreKarsten Spiekermann
Dec 15, 2015·Blood·Hervé Dombret, Claude Gardin
Dec 18, 2015·Scientific Reports·Alexander KuettMichael Fiegl
May 12, 2010·European Journal of Haematology·Lene Sofie Granfeldt OstgårdJan Maxwell Nørgaard
Oct 7, 2014·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Alena M PfeilZsolt Szabo
Sep 26, 2006·Best Practice & Research. Clinical Haematology·Dietger NiederwieserHaifa Al-Ali
Oct 11, 2005·Critical Reviews in Oncology/hematology·Dietger NiederwieserHaifa Al-Ali
Nov 14, 2015·Biogerontology·Anne Marie Vestergaard HentenPernille Sarup
Aug 28, 2014·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Grace KamGee Chuan Wong
Aug 27, 2017·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Matti AaproVicente Valero
Oct 20, 2018·Blood Advances·Nikola P KonstandinKarsten Spiekermann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

© 2021 Meta ULC. All rights reserved